When a person is suspected to have cancer the doctor will ask for certain tests to be performed with blood or/and biopsy from a suspected area. The results obtained after analyzing these samples will help guide the diagnosis and plan further advanced tests and/or treatment. Blood is always required to when blood cancers is suspected (for preliminary examination prior to the confirmatory bone marrow cell studies).
In other cancers blood is important as it gives information on the vital organs like heart, liver and kidney. Blood is also required for complete blood count (CBC) where the blood components the red blood cells (RBC), white blood cells (WBC) and platelets. All these tests will give doctor an idea of how well these organs are functioning and if they’ve been affected by cancer.
Blood is also needed to detect certain abnormal immune system proteins (immunoglobulins) that are sometimes elevated in people with multiple myeloma. Blood is also important to detect tumor markers like the prostate-specific antigen (PSA) for prostate cancer, cancer antigen 125 (CA 125) for ovarian cancer, calcitonin for medullary thyroid cancer, alpha-fetoprotein (AFP) for liver cancer and human chorionic gonadotropin (HCG) for germ cell tumors, such as testicular cancer and ovarian cancer.
MIO has state of the art clinical laboratory and these tests are done regularly Complete Blood Count (CBC)
- Fine needle bone marrow aspiration
- Liver Function tests
- Kidney/Renal Function tests
- Cardiac Function tests
- Thyroid Function test
- Microbial cultures
- Tumor Markers (PSA, CA 125, CA 15.3, CEA, AFP, Beta-HCG)
- Conventional histopathology with Hematoxylin-Eosin staining
- Advanced immunohistochemistry for ER, PR, Her2-Neu, Ki67
The reporting time for most biochemical tests are within 1.5 hours of blood drawing, 3 days for FNAC and punch biopsies and 5 days for single surgical samples and 7-9 days for metastatic/large surgically operated tumors.
Accurate pathological findings are the cornerstone in cancer diagnosis and planning treatment. Recognizing this we at MIO have the services of five highly experienced pathologists who cumulatively decide upon the tumor status. Still at times, when encountering rarest of the rare types and or highly complicated cancers we also send the samples for further confirmation and validation to senior most cancer pathologists across India. We do this with extra care because we know its importance and want to give the best service for our patients.
We tie up with dedicated pathologist and experts from all over India for site specific cancers so that we get the accuracy in diagnosis and type of cancer as it’s vital in deciding the management. MIO believes in pooling the best experience for patients benefit